Canadá - inglês - Health Canada

omega laboratories limited - cisatracurium (cisatracurium besylate) - solution - 2mg - cisatracurium (cisatracurium besylate) 2mg - neuromuscular blocking agents

Canadá - inglês - Health Canada

omega laboratories limited - cisatracurium (cisatracurium besylate) - solution - 2mg - cisatracurium (cisatracurium besylate) 2mg - neuromuscular blocking agents

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cisatracurium besilate, quantity: 0.669 % w/v - solution - excipient ingredients: benzenesulfonic acid; water for injections - cisatracurium-aft is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cisatracurium besilate, quantity: 0.268 % w/v - solution - excipient ingredients: water for injections; benzenesulfonic acid - cisatracurium-aft is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cisatracurium besilate, quantity: 0.268 % w/v - solution - excipient ingredients: benzenesulfonic acid; water for injections - cisatracurium-aft is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cisatracurium besilate, quantity: 0.268 % w/v - solution - excipient ingredients: water for injections; benzenesulfonic acid - cisatracurium-aft is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Canadá - inglês - Health Canada

abbvie corporation - atracurium besylate - liquid - 10mg - atracurium besylate 10mg - neuromuscular blocking agents

Estados Unidos - inglês - NLM (National Library of Medicine)

abbvie inc. - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium 10 mg in 1 ml - nimbex is indicated: - as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age - to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the icu - to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older limitations of use nimbex is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. nimbex is contraindicated in patients with known hypersensitivity to cisatracurium. severe anaphylactic reactions to nimbex have been reported [see warnings and precautions (5.4)] . the use of 10 ml nimbex multiple-dose vials is contraindicated for use in pediatric patients less than 1 month of age and low birth-weight infants because the formulation contains benzyl alcohol [see warnings and precautions (5.2) and use in specific populations (8.4)] . risk summary there are no adequate

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - cisatracurium besilate -

Estados Unidos - inglês - NLM (National Library of Medicine)

abbvie inc. - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium 10 mg in 1 ml - nimbex is indicated: - as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age - to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the icu - to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older limitations of use nimbex is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. - nimbex is contraindicated in patients with known hypersensitivity to cisatracurium. severe anaphylactic reactions to nimbex have been reported [see warnings and precautions ( 5.4 )] . - the use of 10 ml nimbex multiple-dose vials is contraindicated for use in pediatric patients less than 1 month of age and low birth-weight infants because the formulation contains benzyl alcohol [see warnings and precautions ( 5.2 ) and use in specific populations ( 8.4 )] . risk summary the 10 ml ni